Medisca Launches Global Peptide Division

 New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine

 

(BUSINESS WIRE)--Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks.

The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation.

For Medisca, the opportunity is familiar.

More than 35 years ago, the company was founded to help close the gap between the pharmaceutical standards compounders needed and the quality ingredients they could readily access. Today, as peptides emerge as an important area of pharmaceutical innovation and personalized medicine, Medisca sees another defining moment for the industry; one where quality, regulatory responsibility and responsible access will be critical to the category’s future.

The category is growing. Medisca intends to help define the standard.

“When I founded Medisca, I saw an opportunity to bring pharmaceutical compounding closer to the standards of traditional pharma by giving compounders better access to API-grade ingredients and holding those ingredients to a higher standard,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “Today, I see a similar opportunity with peptides. We are not entering this space to follow it. We intend to help shape it.”

Defining a higher standard for peptide quality

Medisca’s approach begins at the source. The company has selected established manufacturing partners that share its quality-first mindset, prioritizing pharmaceutical experience, demonstrated quality systems, manufacturing expertise, and strong quality and compliance practices.

Medisca will apply established processes for manufacturer qualification, product testing, documentation and supply-chain oversight to the peptide APIs it brings to market. These controls are particularly important for peptides, where manufacturing complexity, characterization, purity, and peptide-related impurities present distinct quality considerations. Medisca is committed to operating within applicable regulatory frameworks and supporting responsible access to peptide APIs.

Building an Integrated Peptide Platform

Medisca Peptides extends beyond API supply, bringing together formulation expertise, compounding technologies and equipment, analytical services, education and technical support.

By connecting these capabilities within one platform, Medisca aims to support healthcare professionals and pharmaceutical partners with both the ingredients and expertise needed to navigate the evolving peptide landscape.

“Healthcare professionals and pharmaceutical partners need confidence in the quality and source of a peptide API, but they also need the expertise and infrastructure to put innovation into practice,” said Charlie Guerini, Chief Commercial Officer of Medisca. “That is what we are building with Medisca Peptides: an integrated platform that brings together a growing API portfolio, carefully selected manufacturing partners, reliable supply and the technical expertise our customers have trusted for decades.”

Shaping the Future of Peptide Innovation

The launch marks the beginning of a broader, multi-year strategy to establish Medisca as a global leader in peptide quality, supply and innovation.

Medisca will expand its peptide API portfolio and strategic manufacturing relationships while investing in the scientific, analytical, formulation, technical and educational capabilities needed to advance opportunities across pharmaceutical and personalized medicine.

Beyond supply, Medisca will take an active leadership role in shaping the future of peptides, advocating for added guardrails, transparency, responsible access and appropriate quality standards while working alongside manufacturers, healthcare professionals and industry stakeholders as science, regulation and clinical practice evolve.

The ambition is clear: to help define the next generation of peptides by bringing together the quality, expertise and integrated solutions needed to advance the category.

Medisca Peptides will begin rolling out across select global markets, with additional portfolio, strategic partnership and capability announcements to follow.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917717977/en/

Permalink

https://www.aetoswire.com/en/news/1709202657395

Contacts

Medisca Communications

communications@medisca.com

1-800-665-6334

Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right

 GENEVA - Thursday, 17. September 2026

Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life.

 

(BUSINESS WIRE)--Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction.

Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the places that are hardest to clean, including along the gumline, between teeth and around molars. In fact, 80% of people miss at least one area when brushing, and 60% miss their molars. Over time, that plaque buildup can impact oral health and well-being.

“People brush every day, but brushing effectively in the areas that matter most is not always easy,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. "Oral-B iO was designed around a simple reality: brushing well is harder than most people think. It helps make a superior clean easier to achieve by guiding people to brush more thoroughly and with the right pressure."

The proof is clear: Oral-B iO cleans better

Across 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked first for plaque removal and gingivitis reduction in an independent 2026 peer-reviewed network meta-analysis.

The findings add to a broader body of evidence supporting Oral-B superiority, including more than 120 peer-reviewed publications on Oral-B round-head technology and cleaning performance.

Study after study confirms Oral-B iO technology cleans better, removing more plaque and helping people achieve healthier gums. Oral-B iO removes 100% more plaque than a manual toothbrush and delivers 100% healthier gums. Clinical evidence shows Oral-B iO helps 88% of people with early gum problems get back to healthy gums, four times more than manual brushing, and is 60% more effective than a premium sonic toothbrush along the gumline, where gum issues often persist.

“Effective plaque control is foundational to gum health, but many patients struggle to maintain the right technique, brushing time, pressure and coverage at home,” said Prof. Liran Levin, Professor of Periodontology and the Chair of the Department of Specialty Dentistry at the Northeast Ohio Medical University. “What stands out in this evidence is that Oral-B iO is not only shown to remove more plaque and support healthier gums, but also it is designed to help people brush thoroughly, use the right pressure and sustain better brushing every day. That is where innovation can make a meaningful difference between dental visits.”

Brushing well is harder than most people think and not all brushes, even power brushes, clean the same. Oral-B iO makes a superior clean easier.

Oral-B iO's superiority starts with its oscillating-rotating technology, paired with Oral-B's unique dentist-inspired round brush head, to make a superior clean easier to achieve. The round head surrounds and adapts to each tooth, helping remove plaque where it builds most. Synchronized rotations, micro-vibrations and smart pressure guidance help people brush more completely, clean thoroughly yet gently, avoid brushing too hard, and reach difficult-to-clean areas with less effort.

Simply by switching to iO, people already brush better: research shows 84% of people reached all inside surfaces of teeth after one week of use, significantly more than earlier research showing only 44% with manual brushing.

Better brushing habits start early

The challenge is even more important for children who are still learning how to brush effectively. Good oral-health habits start early, but children need help building the motivation, technique and twice-daily routine that make effective brushing easier to sustain over time.

Oral-B iO Kids helps make brushing easier and more engaging. In product-use research, 90% of children say they love brushing with Oral-B iO Kids, 84% of parents say their child is motivated to brush twice a day for two minutes, 83% of children say the toothbrush makes them want to brush more often, and 88% of children say Oral-B iO Kids makes it easy to brush all areas of their mouth.

Oral-B iO Kids removes 1.5x more plaque than a manual toothbrush, including in hard-to-clean molars, and is the only electric toothbrush technology to have earned the European Academy of Paediatric Dentistry, EAPD, Seal of Approval for children aged 3+.

“Between work, school, and activities, life gets hectic, and our daily routines don’t always match our best intentions,” said Dr. Jeanette MacLean, DDS, Diplomate, American Board of Pediatric Dentistry, Fellow, American Academy of Pediatric Dentistry. “As a pediatric dentist and a mom, I appreciate features that get kids more interested in brushing, help them take their time, and reach the spots they tend to miss. It’s a little extra help to support healthy habits we ask them to do every day.”

A superior clean is a smart investment in healthier mouths for life

Better brushing habits and healthier gums do more than improve everyday oral health. They can also help reduce the need for more intensive treatment over time. Oral health is connected to overall wellbeing, and prevention at home can help reduce future treatment needs, discomfort and cost over time. A P&G and American Academy of Family Physicians survey found that many people care about oral health, but very few spontaneously connect oral health with whole-body health, highlighting an opportunity to make daily oral care feel more like an act of prevention.

Prevention also matters for the environment. A peer-reviewed life cycle assessment published in the Journal of Dentistry found that managing advanced periodontal disease can be associated with up to approximately 10 times higher environmental impact compared with maintaining periodontal health through at-home prevention. The study also found that clinical interventions account for about 90% of total environmental impact across the modeled periodontal pathway, reinforcing prevention at home as an important lever for patients, healthcare systems and the environment.

“A superior clean is not just about how your teeth feel today,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. “By helping people remove more plaque, maintain healthier gums and support healthier mouths, Oral-B iO helps turn daily brushing into a simple habit that supports long-term oral health.”

Designed for real mouths and real brushing habits

Oral-B iO was designed around a simple truth: every mouth is different. Real mouths have curves, tight spaces, hard-to-clean molars and areas people often miss. Oral-B’s unique round head surrounds and adapts to each tooth, while advanced technology helps guide people to clean thoroughly yet gently, use the right pressure, and build better brushing habits.

For consumers, Oral-B iO makes a superior clean easier to achieve every day. For parents, Oral-B iO Kids helps make better brushing more engaging and easier to support. For dental professionals, Oral-B iO helps patients turn advice into action between visits.

Because when brushing well is harder than most people think, the best technology is the one that makes getting it right easier, every day. No wonder why Oral-B is the #1 toothbrush brand used and recommended by dentists worldwide and trusted by millions of consumers around the world.

About Oral-B

Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260911054017/en/

Permalink

https://www.aetoswire.com/en/news/1709202657390

Contacts

For more information please contact:

Cristina Morillogomez, morillogomez.c@pg.com

TOURISE Unveils 2027 Summit Under the Theme “Alliances That Move the World”

 RIYADH, Saudi Arabia - Thursday, 17. September 2026 AETOSWire Print 

Second global tourism summit to convene renowned leaders in Riyadh, March 23-25, 2027

First confirmed speakers announced, including leaders from Booking Holdings, Marriott, Hilton, Intrepid Travel and S4 Capital

Theme calls for new alliances across tourism, technology, investment and government to shape the sector’s next 50 years

 

(BUSINESS WIRE)--Under the patronage of His Royal Highness Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE, today announced the TOURISE 2027 Summit, taking place in Riyadh from March 23-25, 2027. Building on the inaugural TOURISE Summit in November 2025 and a year of collaboration since, the 2027 edition will run under the theme “Alliances That Move the World.” Over three days, leaders will focus on the partnerships, investments and actions needed to advance the global tourism agenda over the next 50 years.​

The Summit will convene public and private sector leaders across tourism, technology, investment, sustainability, culture, mobility and government to tackle the sector’s most pressing opportunities and challenges and help shape the next era of global tourism.​ At the inaugural Summit, TOURISE announced USD 113 billion in portfolio investments spanning hotels, integrated destinations, wellness, retail, talent development and AI-powered platforms, demonstrating the potential of public and private sector collaboration to translate ambition into investment and action.​

 

The first confirmed speakers for the 2027 Summit were also announced and include leaders from organizations such as Marriott, Wego, Switzerland Tourism and Technogym — with many more to come. Together, they represent organizations shaping how people travel, connect, invest and experience the world.​

TOURISE 2027 is also backed by a growing roster of partners and sponsors, including stc, Dar Al Arkan, The Avenues, Qiddiya City, Aseer Development Authority, Saudia, Jeddah Central, Taiba, Tourism Development Fund, Red Sea Global, Almosafer and Snapchat, reflecting the platform’s role in connecting public and private sector across the tourism value chain.

His Excellency Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE, said:​

“The future of tourism will be shaped not by any single destination, company or institution, but by the strength of the alliances we build between the public and private sector. Saudi Arabia has seen firsthand what becomes possible when ambition, investment and partnership move together. Through TOURISE, we are taking that experience to the global stage, connecting leaders across sectors and markets to turn shared ambition into action. In March, we invite the world to Riyadh to build the alliances that will shape the next 50 years of tourism.”​

Gloria Guevara, President and CEO of the World Travel and Tourism Council, and panelist at today’s announcement, added:​

“The next chapter of tourism will be defined by collaboration at a scale we have never seen before. ‘Alliances That Move the World’ captures the opportunity before us: to connect industries, capital and ideas in ways that create meaningful progress for destinations, businesses and communities. TOURISE creates the space for leaders to move beyond discussion and work together on practical solutions for the future of travel.”​

TOURISE is backed by a Board of Trustees chaired by His Excellency, with global experts from online travel agencies, tour operators, hospitality, global tourism bodies, entertainment and media.​

Stakeholders interested in participating in the TOURISE 2027 Summit are encouraged to submit a request for an invitation and join the growing global community helping to shape the future of tourism.

Request an invitation here.

For the latest updates on speakers, research, partnership opportunities and Summit announcements, visit TOURISE.com.​

About TOURISE ​

TOURISE is the world’s premier platform for redefining and shaping the future of tourism. Created by the Saudi Ministry of Tourism, TOURISE launched in 2025, with its inaugural Summit taking place November 11-13 in Riyadh.​

A year-round global platform, TOURISE brings together leaders from government, business, investment, tourism and technology to turn bold ideas into action, unlock investment and help build a tourism sector that is sustainable, equitable and future-focused.​ This is where the next 50 years of tourism are shaped.​

For more information about TOURISE, visit TOURISE.com​

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916467896/en/

Permalink

https://www.aetoswire.com/en/news/54605693

Contacts

 

For further details contact: media@TOURISE.com

Beacon Acquires Haize Labs to Power AI for the Real Economy

TORONTO & SAN FRANCISCO - Thursday, 17. September 2026 AETOSWire 

Haize Labs leadership will anchor Beacon’s new applied AI research group, accelerating the deployment of AI across the essential businesses Beacon owns

 

(BUSINESS WIRE)--Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies.

Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry.

The addition of the Haize Labs team will strengthen this centralized technology platform, which provides shared engineering, AI, product and go-to-market capabilities to Beacon’s portfolio of 45 software companies with customers across recreation, utilities, education, government, manufacturing and other essential industries.

Key focuses for Beacon’s new Applied AI Research Group include: creating reusable AI infrastructure that compounds across Beacon’s portfolio without erasing the local context of each company; translating domain expertise into evaluation and feedback systems that define what good looks like in each business; building continuous testing, red teaming and observability for AI agents before and after deployment; and developing AI products that reduce administrative burden, improve customer service and help the portfolio businesses grow.

“Main Street businesses deserve access to the same caliber of AI talent and technology as the world’s largest companies,” said Nilam Ganenthiran, Founder and CEO of Beacon. “Haize Labs brings exceptional engineers to Beacon who know how to find where AI fails and make it better. Together, we’ll build AI our customers can count on, in the software they already use and trust.”

“The Fortune 500 will have no shortage of AI. The harder problem is making AI useful for the businesses that power the rest of the economy, where most humans work and receive value,” said Leonard Tang, Co-Founder and CEO of Haize Labs, who joins Beacon as VP of AI Research. “Haize Labs was founded with the mission of building AI that any business can depend on. Now, our work will be put directly to use for Beacon’s broad and growing portfolio of essential businesses.”

About Beacon

Beacon is the first centralized AI holding company. Beacon acquires software businesses serving customers across the traditional economy and equips them with AI infrastructure to help them grow. Beacon is building the world’s leading AI operating system that maps how companies operate, so the value compounds for the entire portfolio with each additional acquisition. The company is headquartered in Toronto, ON. Learn more at https://www.beaconholdings.com/.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917239094/en/

Permalink

https://www.aetoswire.com/en/news/1709202657402

Contacts

Media Contact

press@beaconsoftware.com

Thales Unveils HexaForce: AI-Powered, Sovereign Command and Control for NATO and Allied Nations

 Built on an open, interoperable architecture co-designed with armed forces, HexaForce was successfully tested during NATO CWIX 2026.

HexaForce is tailored for high-intensity warfare, supporting command requirements for over 100,000 personnel where operational tempo requires the extensive, targeted deployment of AI.

Thales’ multi-domain solution (covering land, sea, air, cyber, space, and information operations) is already available.

 

(BUSINESS WIRE)--Thales, a global leader in advanced technologies across Defence, Aerospace, and Cyber & Digital, has announced the launch of HexaForce, its next-generation AI-enhanced multi-domain command and control (C2) system. Purpose-built to support national sovereignty, HexaForce provides a rapid, battle-tested response to the massive growth in operational data and the accelerating pace of conflicts.

“Some armed forces require a dedicated data platform, while others need operational cross-domain interfaces to link up with allies and complete their systems, or faster multi-domain command functions leveraging state-of-the-art artificial intelligence. With HexaForce, Thales provides a sovereign solution tailored to each of these operational needs, setting a new benchmark in multi-domain C2 for NATO and allied nations amidst rising high-intensity conflicts.” — Christophe Salomon, Executive Vice-President, Secure Communications and Information Systems, Thales

1. A Multi-Domain Command and Control System

HexaForce operates seamlessly across all operational domains: land, air, sea, cyber, electromagnetic spectrum, space, and information operations. Featuring a resilient, distributed architecture, this platform orchestrates existing systems across national armed forces and coalitions to accelerate decision-making and secure operational advantage at every level of command.

2. Enhanced Capabilities Driven by cortAIx AI

HexaForce harnesses the artificial intelligence capabilities of cortAIx, Thales’ dedicated AI accelerator, which brings together 800 engineers and data scientists working in close alignment with the Group’s defence experts.

By integrating cutting-edge Large Language Models (LLMs) and agentic AI, HexaForce delivers tangible gains for operators across every phase of a mission:

Shorter planning cycles

Richer operational picture awareness

Real-time sharing and consolidation of tactical and operational situational pictures

Accelerated decision-making

Enhanced effector allocation

Optimised in-the-field maintenance and support.

By leveraging AI, HexaForce dramatically scales up data processing and operational intelligence. It automates the analysis, correlation, and prioritisation of massive data streams from military, open-source and civilian origins, significantly boosting military agility and tempo. Live trial phases are currently paving the way for full-scale deployment, targeting an increase in capacity from 100 to 1,000 targets processed per day.

This operational superiority draws directly on operational feedback from Artemis.IA—a data-centric platform deployed with the French Ministry of Armed Forces since 2023, which has proven its capability in multi-source data processing and AI scaling.

3. Seamless Integration from Tactical to Strategic Levels

HexaForce is currently the only market solution capable of orchestrating all assets across armed forces and coalition partners, spanning strategic commanders down to tactical units. It relies on a distributed data network designed to remain resilient even under severely degraded communications conditions.

4. Open and Interoperable Architecture

HexaForce combines a core software platform with multi-domain command applications. Built on open-source standards, its open and interoperable architecture has been rigorously tested, notably during the NATO CWIX 2026 exercise. This design ensures full sovereign control over incoming and outgoing data feeds without requiring data exposure.

HexaForce natively supports Data-Centric Security (DCS) and Federated Mission Networking (FMN) standards. Unlike closed, proprietary systems, it enables nations to integrate their chosen technology partners within a controlled, modular environment—delivering maximum operational performance alongside full national sovereignty. As an open, multi-domain solution, HexaForce provides complete C2 capabilities, including seamless connectivity with legacy systems provided by third-party vendors.

5. Co-developed with Frontline Forces

HexaForce is an agile milestone in military software development, built using short feedback loops alongside armed forces to continuously integrate end-user requirements at every stage.

About Thales

 

 

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.

 

 

The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies.

 

 

Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

 

 

PLEASE VISIT

Thales Group

Thales

Recent images of Thales and its Defense, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917956437/en/

Permalink

https://aetoswire.com/en/news/1709202657384

Contacts

MEDIA CONTACT

Thales, relations médias

marion.bonnet@thalesgroup.com

+33(0)660384892

 

IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed

 New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability

(BUSINESS WIRE) -- IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions.

“We believe the future of dairy nutrition is helping cows receive more value from the nutrients in their feed,” said Regina Cortada, vice president, Animal Nutrition & Health for IFF Health & Biosciences. “Our research challenged the long-held assumption that dairy cows fully utilize the phytate contained in feed. We found that phytate breakdown is often incomplete, leaving valuable nutrients unavailable to the animal. Omni-Bos PHY was developed to unlock those nutrients and help producers improve feed efficiency, support sustainability goals and increase profitability.”

Global milk production is projected to grow 2% annually over the coming decade, increasing pressure on producers to improve productivity while managing feed costs and sustainability targets. Feed remains one of the largest expenses in dairy production, making nutrient efficiency a critical opportunity for producers seeking to improve profitability and performance.

Phytate — a naturally occurring compound found in many feed ingredients — can bind nutrients and reduce their availability to the animal. While phytase technology has been widely used in poultry and swine production for decades, its effectiveness in dairy cattle has historically been limited.

“Traditional phytase enzymes were not designed to withstand the unique digestive conditions of dairy cattle,” said Ester Vinyeta, innovation director, Animal Nutrition & Health for IFF Health & Biosciences. “Omni-Bos PHY was specifically developed for ruminants and is designed to remain active where it can unlock nutrients that would otherwise remain inaccessible. This enables dairy producers to extract more nutritional value from existing feed ingredients while reducing nutrient losses.”

By helping cows utilize more of the protein, phosphorus and minerals already present in feed, Omni-Bos™ PHY can reduce reliance on supplemental phosphorus and protected amino acids while supporting the use of alternative protein sources. The result is improved feed efficiency, lower feed costs and reduced nitrogen and phosphorus excretion.

The enzyme is suitable for use in concentrates, premixes and total mixed rations and has been evaluated extensively throughout product development. In one study, Omni-Bos™ PHY decreased undegraded phytate in the abomasum by approximately 70% compared with a control diet. Additional studies in lactating dairy cows demonstrated that Omni-Bos™ PHY:

Improved phosphorus and phytate digestibility

Reduced nitrogen and phosphorus excretion

Increased digestibility of nutrients including crude protein and calcium

Collectively, these findings demonstrate Omni-Bos™ PHY’s ability to improve nutrient utilization and help dairy producers maximize the value of every ton of feed while supporting more sustainable production systems.

To learn more about Omni-Bos PHY, visit https://www.iff.com/animal-nutrition/products/omni-bos-phy

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent and biosciences, we’re innovating for the future. We deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916599752/en/

Permalink

https://aetoswire.com/en/news/1709202657391

Contacts

Paulina Heinkel

VP, Branding and Communication for IFF Health & Biosciences

media.request@iff.com

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing

ZUG, Switzerland - Wednesday, 16. September 2026


    Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121
    Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1
    These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic acid (HA) injectables portfolio in China, one of the world's fastest-growing aesthetics markets, through evidence generation that supports broader patient access and additional treatment areas.1-3

Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.1,4-8 Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes within the tissue to offer natural-looking results, helping to soften temple hollowing, restore facial balance, and create a refreshed appearance.1,4,9 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Volyme enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals10-12

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.12-14 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years.12-14 Following the launch of Restylane Volyme in China for the treatment of the mid-face region, this study provides new evidence supporting its effectiveness and safety for correction of temple hollowing, in a market where there are currently limited options.1

“Temple hollowing is a common concern among patients seeking facial rejuvenation, particularly for those experiencing medication-driven weight loss, yet treatment options in China remain limited. These results demonstrate that Restylane Volyme can provide effective, natural-looking correction with high levels of patient satisfaction and a robust safety profile. As demand for individualized aesthetic treatments continues to grow in China, expanding the range of evidence-based solutions available will be increasingly important.”

PROF. ZHAO HONGYI
STUDY PRINCIPAL INVESTIGATOR,
DIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL, CHINA

In this randomized, evaluator-blinded study, 162 adults were recruited across six sites in China and were split 2:1 into two groups; the Restylane Volyme treatment group or the no treatment control group.1 Results showed that for patients in the Restylane Volyme group:

    Strong effectiveness
        94.4% of patients demonstrated at least 1-grade improvement in temple hollowing, from baseline, in both temples at Month 6 after last treatment, compared to just 2.0% in the control group at Month 6 after baseline.1
        Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates remained high through Month 121
        91.3% of patients showed improvement on the Global Aesthetic Improvement Scale for both temples through Month 12, according to the treating investigator1
    High satisfaction
        Patient satisfaction was high at Month 3 and remained consistently high, with more than 84% of patients satisfied with both the natural look and natural feel of their temples through Month 121
        More than 90% said they would recommend the treatment to a friend, and over 86% would have the treatment again1
        Half of the participants felt comfortable returning to social engagement within 24 hours after initial treatment1
    Robust safety
        Restylane Volyme was generally well tolerated, with no treatment-related serious adverse events and no granulomas1

“These positive topline results further strengthen the clinical evidence supporting Restylane Volyme and mark an important step in our strategy to expand the Restylane portfolio in China. As one of the world’s fastest-growing aesthetics markets, China presents a significant opportunity to address evolving patient needs with science-backed, differentiated solutions. This study supports our ambition to broaden the indications available to practitioners and patients, while reinforcing Galderma’s leadership in Injectable Aesthetics through continued investment in innovation and clinical research.”

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA

With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs.15-16 China is one of the fastest growing aesthetics markets worldwide and HA fillers are among the top 10 most-sold aesthetics products.2,3 This study highlights Galderma’s commitment to expand the availability of its Restylane portfolio to more patients and practitioners in China and exemplifies its continuing expansion in a growing and strategically significant market.

About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.17-19 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.5,20,21 Powered by NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4,6-8 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results. 18,22,23 Approved indications vary by market.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

    Galderma. Data on file. 43CH2401
    Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026. Available online.
    Grand View Horizon. China Aesthetic Medicine Market Size & Outlook, 2026-2033. Accessed September 2026. Available online
    Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
    Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
    Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
    Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
    Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
    Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41(12):1361-9. doi: 10.1097/DSS.0000000000000549
    Restylane® Volyme. IFU. Available online. Accessed September 2026
    Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025
    Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025
    Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg, 2023;39:719-73. doi: 10.1055/a-2148-6321
    Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057
    Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
    Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
    Restylane® EU Instructions for Use. July 2026.
    Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
    Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
    Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
    Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
    Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
    Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915734207/en/

Permalink
https://www.aetoswire.com/en/news/1609202657354

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition

 Abu Dhabi, United Arab Emirates -

As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined.

Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’

Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innovation are reshaping energy systems. Day one featured keynotes from H. E. Abdullah bin Touq Al Marri, UAE Cabinet Member and Minister of Economy and Tourism, and Schneider Electric CEO Olivier Blum, in the presence of H.E. Marie Audouard, Ambassador Extraordinary and Plenipotentiary of the French Republic to the UAE. The summit also featured the launch of the Innovation Hub, the Data Cube, and Olivier Blum’s address on “The Era of Intelligence.”

“We’re entering an Era of Intelligence in which AI is becoming embedded in the physical economy. AI may be digital, but it runs on electricity and depends on the physical systems beneath it,” said Olivier Blum, CEO of Schneider Electric. “As an Energy Technology Partner, we help customers connect energy and operations through data, software, AI and automation, turning intelligence into action to improve performance, resilience and competitiveness. The scale of this shift is clear in the Middle East and Africa, where governments and businesses are investing in energy and digital infrastructure to support industrial transformation and long-term growth.”

The summit also featured the release of the company’s 2026 Industrial AI in CPG Study for the UAE, which found that 59% of UAE manufacturers expect transformational AI adoption by 2030, compared with 42.2% globally. Walid Sheta, President, MEA Zone, said, “As our region’s manufacturers move faster and more confidently on industrial AI than anywhere else, it’s our responsibility to make sure that confidence is well-founded. Cybersecurity, resilience, and return on AI investment are the concerns we hear about most often from customers, and rightly so.”

Schneider Electric reaffirmed its commitment to collaborating with governments, customers, and partners to accelerate intelligent, resilient energy infrastructure.

Permalink

https://www.aetoswire.com/en/news/1609202657358

Contacts

Press contact:

Mohammed Abdulla

mabdulla@apcoworldwide.com

www.se.com

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

 MOUNTAIN VIEW, Calif. - Wednesday, 16. September 2026 AETOSWire  

AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trials

Rubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle

 

(BUSINESS WIRE) -- Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind.

RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mechanism that clears pathologic senescent cells and promotes a redox reset by modulating NRF2 pathways in stressed aged cells, including stem and progenitor cells. Ex vivo studies on a human hair follicles AGA model resulted in the restoration of hair follicle growth, as depicted in the image above.

In an independent ex vivo human AGA model — conducted using intact human hair follicles from male patients with AGA, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in AGA patients — RLS‑1496 demonstrated statistically and highly statistically significant increases in hair follicle elongation compared to vehicle control at 2 doses, respectively, with the highest dose showing a numerically greater trend in mean elongation than finasteride.

Hair follicle elongation at Day 6 was greater with RLS-1496 versus vehicle across all doses, with the strongest effect at the highest concentration — directionally outperforming standard-of-care finasteride

The pattern is consistent with rescue of the anagen (active growth) phase, when targeting senescent cells from the follicular niche allows stem cell reactivation from the dormant state and the follicle to resume its natural growth program

“The senescent cell biology underlying hair follicle aging is compelling, deeply consistent with what we have seen across our RLS-1496 program, and vastly underexplored as a therapeutic target,” said Rubedo Chief Executive Officer Frederick Beddingfield III, MD, PhD, FAAD. “For the first time, we are bringing a medicine into the clinic designed to clear the aged cells at the root of stem cell dormancy and follicular miniaturization. We are proud to do so in partnership with Dr. Pariser, and we are moving with the same urgency that made RLS-1496 the world’s first GPX4 modulator in human trials.”

AGA is the most prevalent form of hair loss globally, affecting approximately 50 million men and 30 million women in the U.S. alone; however, the treatment landscape has seen no genuinely new FDA-approved approaches in nearly 30 years.2 The global AGA market, valued at $3.2 billion in 2025 and projected to reach $6.8 billion by 2035, is defined by two therapies — minoxidil and finasteride — that slow the hormonal signals that cause hair follicles to progressively shrink and degenerate, a process known as follicular miniaturization. Follicular miniaturization is the biological hallmark of AGA, in which each successive growth cycle produces a thinner, shorter hair until the follicle can no longer produce visible hair. Neither therapy addresses the senescent — aged and dysfunctional — cells now understood to accumulate within the follicular niche and drive this miniaturization at the cellular level.3,4,5

Unlike existing therapies that target secondary hormonal causes of hair loss, RLS-1496 is designed to act on the primary cellular aging mechanism: the accumulation of senescent and stressed dermal papilla cells that actively suppress stem cells, follicular regeneration, and drive progressive miniaturization. By targeting these cells with selective elimination or functional restoration, depending on the cell state, RLS-1496, a first-in-class SenoAdaptive Drug, aims to remove the cellular brake on follicular regeneration itself.3,4,5,6

Rubedo Co-Founder and Chief Scientific Officer Marco Quarta, PhD, will present the ex vivo data, along with additional RLS-1496 data, at the 13th Annual Aging Research & Drug Discovery (ARDD) Meeting at Harvard University, October 1–3, 2026 — the world’s largest dedicated longevity science conference. The presentation marks the first time a GPX4 modulator program in hair loss will be presented at a major longevity science conference.

Dr. Quarta said, “RLS-1496 appears to act at several convergent points in the AGA disease cascade — where we believe it acts by clearing senescent cells, suppressing follicular regeneration, reducing inflammatory SASP signaling, while also modulating NRF2 pathways and activating Wnt/β-catenin pathways governing anagen re-entry. To our knowledge, no approved AGA therapy operates at this level of biology.”

Rubedo’s proprietary ALEMBIC™ spatial transcriptomics applied to patient hair follicle biopsies identified senescence markers and transcriptomic signals consistent with activation of the follicular regenerative cascade, including the expansion of hair follicle progenitors, and downregulation of key drivers of the follicle regression phase — providing human clinical evidence that RLS-1496’s effects on senescent cell biology extend to hair follicle tissue. In preclinical animal studies, RLS-1496 also achieved approximately 32% greater hair regrowth versus vehicle.1,6,7

“The preliminary data we have seen with RLS-1496 are scientifically intriguing and warranted clinical evaluation,” said Dr. Pariser, Professor of Dermatology at Eastern Virginia Medical School and Principal Investigator of Virginia Clinical Research, Inc., who will be leading the RLS-1496 hair loss clinical trial. “The senescence biology underlying AGA is increasingly well-supported in the published literature, and RLS-1496 represents a genuinely novel approach to it. I look forward to seeing what the data show in patients given the ongoing unmet need.”

About RLS-1496 and GPX4 Modulation

Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases. These include immunology and inflammation (I&I), dermatology and skin aging, hair loss, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.

In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to fight disease and also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 can also act as a restorative modulator that induces a vital ‘redox-reset’ through a controlled hormetic response in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis. This dual-action mechanism represents a novel drug category—Adaptive SenoTherapeutics.

RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders, including hair loss. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

References

Rubedo Life Sciences. RLS-1496 demonstrates hair follicle elongation in a DHT-challenged ex vivo androgenetic alopecia model. Data on file. 2026.

Global Market Insights. Androgenetic Alopecia Treatment Market Size, Share & Trends Analysis Report. 2026

Bahta AW, Farjo N, Farjo B, Philpott MP. Premature Senescence of Balding Dermal Papilla Cells In Vitro Is Associated with p16(INK4a) Expression. Journal of Investigative Dermatology2008;128(5):1088-1094. doi: 10.1038/sj.jid.5701147

Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen Receptor Accelerates Premature Senescence of Human Dermal Papilla Cells in Association with DNA Damage. PLoS ONE2013;8(11): e79434. doi: 10.1371/journal.pone.0079434

Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative Stress-Associated Senescence in Dermal Papilla Cells of Men with Androgenetic Alopecia. Journal of Investigative Dermatology 2015;135(5):1244-1252. doi: 10.1038/jid.2015.28

Pappalardo A, Kim JY, Abaci HE, Christiano AM. Restoration of hair follicle inductive properties by depletion of senescent cells. Aging Cell2024;24: e14353. doi: 10.1111/acel.14353

Rubedo Life Sciences. RLS-1496 achieves 32% greater hair regrowth versus vehicle in preclinical animal studies. Data on file. 2026.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916811892/en/

Permalink

https://www.aetoswire.com/en/news/1609202657361

Contacts

Investor Contact: Ali Siam, Chief Business Officer alisiam@rubedolife.com | 781-974-9559

Media Contact: Peter Collins, TogoRun p.collins@togorun.com | 908-499-1200

NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence

 New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments

 

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond.

“NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infrastructure will help us deliver a more seamless and connected experience for our Krewe at games and across the digital platforms that we use.”

This partnership launches following the Buccaneers first regular 2026 season game against the Cincinnati Bengals on September 13. The partnership expands NetApp’s relationship with the NFL as the league’s Official Intelligent Data Infrastructure Partner, helping to securely manage, protect, and activate the data behind the league’s operations. Across the NFL, NetApp technology supports demanding real-world workloads, including the storage and availability of game day video used by NFL football operations and club football operations teams. This collaboration has demonstrated how the right infrastructure can help complex, data-intensive organizations operate more efficiently and resiliently.

By using NetApp Keystone, a flexible and simple subscription-based service that adapts to changing business needs, the Buccaneers can accelerate data workloads with industry-leading performance, intelligent data management, and high availability across data centers and cloud environments. The NetApp Platform delivers built-in data security that autonomously detects threats and enables rapid recovery.

“Successful teams achieve meaningful results long before game day by bringing together the right people, trusted data, sound decisions, and disciplined execution,” said Gabie Boko, Chief Marketing Officer at NetApp. “Elite sports show what organizations can accomplish when their people can turn information into confident action. As a Proud Partner of the Tampa Bay Buccaneers, we’re celebrating the preparation, trust, and teamwork that sustain excellence and the Intelligent Data Infrastructure that helps make it possible.”

Additional Resources

NetApp and the NFL Team Up with Intelligent Data Infrastructure

The Unseen MVP of the NFL Season

NetApp Named Presenting Partner of 2026 NFL Madrid Game

NetApp Data Platform Powers Data Operations for Super Bowl LX

About the Tampa Bay Buccaneers

The Tampa Bay Buccaneers are in their 51st season as members of the National Football League and compete in the National Football Conference’s South Division. They were purchased by the late Malcolm Glazer in 1995 and are currently owned by the Glazer Family. Established in 1976, the Buccaneers have totaled 10 division titles, two conference championships and two Super Bowl Championships, including Super Bowl LV that was played on their home field at Raymond James Stadium. The Buccaneers have also been leaders in the NFL in fan engagement, earning a record 12 consecutive No. 1 rankings in overall customer satisfaction in the league’s annual Voice of the Fan survey. Additionally, the franchise is very active in the community, with the Tampa Bay Buccaneers Foundation, the Glazer Vision Foundation and the Glazer Family Foundation. For more information, visit www.buccaneers.com.

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916768662/en/

Permalink

https://aetoswire.com/en/news/1609202657360

Contacts

Media Contact:  

Kenya Hayes  

NetApp  

kenya.hayes@netapp.com  

Investor Contact:  

Kris Newton  

NetApp  

kris.newton@netapp.com  

 

The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision

 

RIYADH, Saudi Arabia - 

The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs

 

(BUSINESS WIRE)--Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination.

Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal.

“As we launch the first Jayasom globally, we are bringing a new dimension to AMAALA’s wellness offering. Its dedicated, all-inclusive wellness retreats combine contemporary, evidence-based practices with Arab and Eastern healing traditions. Its personalized approach complements our ambition for AMAALA to become the world’s most comprehensive wellness destination supporting guests on their long-term health journeys in an exceptional natural environment,” said John Pagano, Group CEO of Red Sea Global.

The resort’s wellness philosophy brings together Arab and Eastern healing traditions alongside contemporary evidence-based practices, reflecting centuries of knowledge exchange across cultures, including contributions from pioneering scholars such as Ibn Sina (Avicenna). The offering spans holistic health, fitness, physiotherapy, nutrition, spa and beauty, supported by consultations, movement and daily activities. Each guest journey is tailored to individual goals including women’s health, couples and family wellbeing, as well as health, weight and lifestyle reset.

Nutrition is an integral part of the Jayasom Wellness Resort AMAALA experience, with a collection of eight dining venues designed to support balanced lifestyles. The resort's restaurants and cafés offer a diverse range of cuisines inspired by regional and international traditions, with an emphasis on fresh, seasonal ingredients and nutritious dishes. Complementing the dining offer are interactive culinary experiences and specialty concepts that encourage guests to explore the role of food in healthy living.

The resort is divided into an adults-only wellness offering and a dedicated experience for families. The adult-only zone provides a sanctuary focused on holistic therapies, physiotherapy, fitness and Pilates, while the family experiences feature age-specific facilities and activities designed to support connection, movement and healthy habits.

The Jayasom Residences comprise a limited collection of two- to four-bedroom beachfront villas, with private pools and expansive sea-facing terraces. Located adjacent to the resort, residents enjoy exclusive privileges such as complimentary wellness retreats, preferred access to treatments and dining, and invitations to Jayasom events worldwide.

Nestled between the Red Sea and the dramatic Tabuk mountains, the resort is surrounded by coastal landscapes providing opportunities for land and water-based activities. This includes hiking, trail running, cycling, kayaking, stand-up paddleboarding, snorkeling and diving.

Along with the rest of the destination, Jayasom Wellness Resort AMAALA is fully powered by solar energy. It also supports the destination’s ambition to achieve a 30% net conservation gain by 2040.

Jayasom AMAALA is the seventh resort to open at AMAALA, marking another milestone in the destination’s phased delivery. In the coming months, a further two resorts will join a growing portfolio of world-class hospitality brands, alongside branded residences, integrated wellness facilities, a marina, curated retail, a marine life experiential institute and destination dining.

About Red Sea Global

Red Sea Global (RSG) is a vertically integrated real estate developer with a diverse portfolio across tourism, residential, experiences, infrastructure, transport, healthcare, and services. This includes the luxury regenerative tourism destinations The Red Sea, which began welcoming guests in 2023, and AMAALA, which welcomed its first guests in 2026.

A third destination, Thuwal Private Retreat, opened in 2024. RSG was also entrusted with development works at AlWajh International Airport, focused on upgrading the terminal and infrastructure.

RSG is a PIF company and a cornerstone of Saudi Arabia’s ambition to diversify its economy. Across its growing portfolio of destinations, subsidiaries, and businesses, RSG seeks to lead the world toward a more sustainable future, showing how responsible development can uplift communities, drive economies, and enhance the environment.

About AMAALA

AMAALA is an unparalleled ultra-luxury wellness destination along the northwestern coast of the Red Sea in Saudi Arabia. Seamlessly blending sea, sun, sports, arts, and culture for an exceptional experience, it is one of the world’s most anticipated destinations developed by Red Sea Global (RSG) with regeneration at its core.

AMAALA officially opened its first resort in summer of 2026, with more than 1,600 hotel rooms set to open across nine different resorts complemented by high-end retail and fine dining experiences upon completion. The destination’s state-of-the-art wellness and spa facilities will offer a comprehensive array of multi-generational programs, services, and various therapies, customized by practitioners and centers pioneering in various medical and wellness fields for a more personalized wellness journey.

Influenced by AMAALA’s natural beauty and the purity of the Red Sea, the destination is where sustainability meets luxury. The aim of AMAALA is to offer the most comprehensive health and wellness experience that will help improve the wellbeing of its guests and community, helping them flourish and thrive.

Two of AMAALA’s hallmark features include Corallium Marine Life Institute, an educational and scientific research center, and the AMAALA Yacht Club, destined to become an international hub for luxury yachting.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916231950/en/

Permalink

https://aetoswire.com/en/news/1609202657362

Contacts

For more information, please contact:

Arwa Alsantli, Manager - Public Relations

+966 56 616 6017

Arwa.Alsantli@RedSeaGlobal.com

 

iQmetrix to Deliver 2026 Telecom Industry Address and Product Announcements, Unveiling the Next Wave of Intelligent Commerce

  VANCOUVER, British Columbia - Tuesday, 15. September 2026 AETOSWire Print 

iQmetrix's annual industry briefing goes global on October 28, pairing a year of worldwide market intelligence with the company's outlook on AI-native commerce and a first look at what's next for its Intelligent Commerce Operating System

 

(BUSINESS WIRE)--iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, today opened registration for the 2026 Telecom Industry Address and Product Announcements, taking place Wednesday, October 28, 2026. For the first time in the event's history, iQmetrix will run two dedicated virtual sessions: one built specifically for European audiences, alongside its long-running North American event. Both are free to attend.

Now in its seventh year, the Industry Address has become the telecom channel's annual checkpoint: an unfiltered read on where the market is heading, delivered by a company that sits at the intersection of telcos, retailers, and the partners who serve them. The 2026 edition draws on a year of research and direct conversations across international markets.

"We spend the year listening — to telcos, to retailers, to the partners building alongside us, in a dozen different markets," said Megan Howse, Senior Vice President, Marketing at iQmetrix. "The Telecom Industry Address is where all of that turns into something the industry can actually use. Adding a European session means we're no longer asking half our audience to take the North American view and translate it."

The 90-minute program runs in two parts. The first covers the trends, pressures, and openings shaping telecom commerce globally. The second is iQmetrix's annual product announcement, including an early look at what is coming next for the Intelligent Commerce Operating System — the category iQmetrix has defined around one orchestrated system connecting point of sale, ecommerce, inventory, activations, and customer journeys, with AI embedded in how the system runs rather than layered on top.

The event is open to the wider industry: telcos, retailers, repair providers, device and accessory manufacturers, distributors, industry media, and the broader telecom ecosystem. Attendees will leave with a clearer read on where the market is moving and practical direction for their commerce strategy in the year ahead.

Session details — Wednesday, October 28, 2026

Europe session: 1:00 p.m. UK / 2:00 p.m. CET / 9:00 a.m. ET / 7:00 a.m. MT

North America session: 12:00 p.m. ET / 10:00 a.m. MT / 9:00 a.m. PT / 5:00 p.m. CET

Both sessions cover the same content; attendees need only join the one that suits their schedule.

Registration is now open here. A recording will be sent to everyone who registers, whether or not they attend live.

About iQmetrix

iQmetrix is the global provider of Intelligent Commerce Operating Systems for telecom. It replaces fragmented legacy stacks with a modern, modular layer that orchestrates telcos, retailers, and OEMs into one intelligent flow across channels and markets. The result is less complexity, lower cost, and the speed to move ahead.

For 27years, iQmetrix has helped the leading brands in telecom grow by providing best-in-class software, services, and expertise. Its solutions powered $17 billion in sales last year, handling nearly 53 million invoices and more than 28 million activations, and are used by more than 370,000 telecom retail professionals across almost 1,000 clients. iQmetrix is a privately held software-as-a-service (SaaS) company with employees in Canada, the U.S., India, and Europe. For more information, visit www.iqmetrix.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260914992633/en/

Permalink

https://www.aetoswire.com/en/news/1509202657312

Contacts

Media Contact

media@iqmetrix.com

Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth

 PARMA, Italy -

Highlights:

David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026.

Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering.

 

(BUSINESS WIRE) -- Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026.

David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development.

Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO.

Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovation has always been at the heart of Chiesi's mission and long-term vision. David's appointment reflects our ambition to accelerate this journey and strengthen Chiesi’s ability to innovate in a healthcare environment that is changing faster than ever. He brings a unique combination of global healthcare leadership, operational experience and exposure to some of the most dynamic areas of biotech innovation, which makes him exceptionally well positioned to guide Chiesi through this next chapter.

On behalf of the Board, I would like to express my sincere gratitude to Jean-Marc Bellemin for his commitment and stewardship during this transition period. I would also like to thank the entire Group Executive Leadership Team for their dedication and collective leadership, which have been instrumental in maintaining the Group's focus and preparing the organization for the next steps."

David Khougazian commented: “I am honored and excited to join Chiesi, a company widely recognized for its strong values, scientific excellence, entrepreneurial mindset and commitment to patients. The healthcare landscape is evolving rapidly, creating extraordinary opportunities to advance innovation and transform patient outcomes. Chiesi has built an impressive foundation, combining scientific expertise and a clear commitment to sustainable growth across generations.

I look forward to working alongside Chiesi colleagues around the world to further strengthen the Group's innovation capabilities, advance its pipeline and partnerships, and create lasting value for patients, healthcare systems and society.”

Chiesi remains firmly committed to executing its patient-centric strategy, advancing innovation across its therapeutic areas, and delivering sustainable growth for the benefit of patients, healthcare systems, communities and the planet.

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi meets verified standards for social and environmental business practices. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com or the website of your local Chiesi affiliate.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915411388/en/

Permalink

https://www.aetoswire.com/en/news/1509202657328

Contacts

Press Info:

Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com

Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com

Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

AMAALA Yacht Club Opens, Putting the Red Sea on the Global Yachting Map

 Luxury sailing, wellness and exploration converge at Saudi Arabia's newest yachting destination

 

(BUSINESS WIRE)--Red Sea Global (RSG), the regenerative tourism developer, has announced that AMAALA Yacht Club has officially begun operations, marking a major milestone in establishing the Saudi Red Sea as a new global destination for luxury yachting, sailing and marine tourism.

Nestled within AMAALA Marina Village, the AMAALA Yacht Club is now welcoming founding members and visiting yachts to moor and explore the destination.

Located approximately 2,000 nautical miles from Monaco, the club provides a new winter destination for the world’s luxury sailing community, which traditionally migrates from the Mediterranean to the Caribbean or Indian Ocean from October. Positioned closer to the Mediterranean than the Caribbean, AMAALA offers an attractive winter cruising hub and a strategic gateway to the Indian Ocean.

“The AMAALA Yacht Club marks the emergence of a truly global yachting destination, offering unparalleled access to the stunning Saudi Red Sea coast. More than a world-class facility, it brings together luxury, wellness, and regenerative tourism in a way that is unique anywhere in the world,” said John Pagano, Group CEO of Red Sea Global.

AMAALA Marina features 119 berths, can accommodate superyachts of more than 100 meters and offers a comprehensive marine services, including fueling with maintenance and repair facilities in the coming years. The 7,900-square-meter AMAALA Yacht Club serves as a premier hub for the destination’s maritime community, offering world-class facilities, services and experiences for residents and visiting yacht owners alike. Berthing and mooring fees are comparable to leading European yachting destinations while yacht owners securing permanent moorings benefit from a range of exclusive privileges through selected resort partners.

Within AMAALA Yacht Club, members and guests can enjoy a selection of dining and social spaces, including AMAALA Lounge, ANQA, 27°C and The Deck, alongside a rooftop pool, private meeting suites and dedicated areas for social gatherings and events.

The AYC Academy will also offer sailing programs and watersports experiences, supporting participation at every level and across all age groups.

The club plays a key role in advancing Saudi Arabia’s presence on the global sailing stage. This includes being a centerpiece of the Grand Finale of The Ocean Race 2027, one of the world’s most prestigious sailing competitions. It will also host a series of international yachting events throughout the year.

The club’s members and guests will enjoy access to newly opened luxury resorts in AMAALA such as Four Seasons, Six Senses, Rosewood, Equinox, and Nammos with two additional resorts opening in the coming months. Visitors can revel in the elaborate wellness offerings, elite water sports, cultural programming, art installations and vibrant social spaces, creating a distinctive destination that reimagines the yachting lifestyle. With average temperatures of 26°C throughout the season and average lows of 23°C, AMAALA Offers a comfortable year-round cruising environment for yacht owners, guests and crew. Located just 45 minutes from Alwajh International Airport, the destination also provides convenient access and connectivity for international visitors.

Designed by HKS Architects, the yacht club draws inspiration from the sculpted rock formations of the Red Sea coastline, expressed through its cantilevered terraces, maritime heritage and traditional Arabian architectural forms. The landmark facility is designed to serve as long-term gathering place for the international sailing and yachting community.

Like the wider destination, AMAALA Yacht Club is powered entirely by renewable energy, reflecting Red Sea Global's commitment to responsible development and regenerative tourism.

About Red Sea Global

Red Sea Global (RSG) is a vertically integrated real estate developer with a diverse portfolio across tourism, residential, experiences, infrastructure, transport, healthcare, and services. This includes the luxury regenerative tourism destinations The Red Sea, which began welcoming guests in 2023, and AMAALA, which welcomed its first guests in 2026.

A third destination, Thuwal Private Retreat, opened in 2024. RSG was also entrusted with development works at AlWajh International Airport, focused on upgrading the terminal and infrastructure.

RSG is a PIF company and a cornerstone of Saudi Arabia’s ambition to diversify its economy. Across its growing portfolio of destinations, subsidiaries, and businesses, RSG seeks to lead the world toward a more sustainable future, showing how responsible development can uplift communities, drive economies, and enhance the environment.

About AMAALA Yacht Club

AMAALA Yacht Club is a new international hub for luxury yachting within AMAALA, the ultra-luxury wellness destination in the protected Prince Mohammed bin Salman Royal Reserve. Combining world-class marina infrastructure, contemporary design and exceptional hospitality, AMAALA Yacht Club serves as a gateway to the Red Sea, one of the world's most unexplored cruising grounds.

The 119-berth marina accommodates superyachts of more than 100 metres and offers a full international port of entry. Situated approximately 200 nautical miles south of the Suez Canal, the yacht club is ideally positioned for vessels looking to explore waters beyond the Mediterranean and Caribbean, while also providing an attractive winter base for both private and charter yachts.

Designed by internationally renowned architects HKS, the 7,900-square-metre clubhouse brings together elegant dining venues, private lounges, a pool deck and year-round programme of sailing and social events. AMAALA Yacht Club is also home to the AYC Academy, which delivers sailing programs for all ages and abilities, helping to inspire the next generation of sailors and establish the Red Sea as an emerging centre for sailing excellence.

AMAALA Yacht Club will host major international sailing events, including The Ocean Race in 2027, cementing its position as a new global hub for yachting and sailing in the Red Sea.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260914160771/en/

Permalink

https://www.aetoswire.com/en/news/1509202657310

Contacts

For more information, please contact:

Arwa Alsantli, Manager - Public Relations

+966 56 616 6017

Arwa.Alsantli@RedSeaGlobal.com

Workiva Advances Regulatory Work with AI Innovation

 LAS VEGAS -

Agent Studio anchors AI capabilities unveiled at Amplify 2026

(BUSINESS WIRE) -- Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders.

Workiva Debuts Agent Studio

Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work.

“With Agent Studio, we're putting the power to build in the hands of the people who know the work and their company the best. But what you build is only as strong as what it's built on,” said Julie Iskow, CEO of Workiva. "Every company has access to AI. What matters is whether your outcomes are traceable, defensible, and can hold up in front of investors and regulators. This is even more important as AI becomes more ubiquitous."

Workiva Broadens Regulatory Reporting Footprint

The release of three new agentic solutions marks Workiva’s expansion into a wider universe of reporting obligations and regulatory work. Starting with what has historically been highly manual regulatory disclosures, such as BEA (Bureau of Economic Analysis) surveys, US Census surveys, and Country-by-Country Reporting, accounting and finance teams will be able to manage a broader range of regulatory requirements within the same connected platform.

Workiva Launches Automated Testing for Internal Audit and GRC

The new agentic solution accelerates testing while maintaining consistency, traceability, and governance. By orchestrating evidence, attribute, and testing agents, the solution replaces manual evidence collection, sample selection, attribute testing, and documentation with a purpose-built workflow that provides full traceability at every step. The result is expanded sampling capacity, broader risk coverage, and the ability to scale testing without scaling manual effort.

"Transformation requires genuine buy-in at every level of the value stream. This work has always demanded process precision. Now it demands velocity, too,” said Keri Tracy, Chief Audit Executive of Newell Brands. “As AI takes on more work, it frees audit professionals to focus on higher-value judgment, interpretation, and risk management. But that only works if people trust the technology. When teams feel heard, valued, and supported through the change, adoption follows naturally, controls strengthen, and the integrity of the process becomes the foundation that withstands any audit or regulatory scrutiny."

For more information about innovations announced at Amplify, visit workiva.com/platform/whats-new. Video demonstrations are available on the Workiva Demo Center, and Amplify attendees can experience them live in the Amplify hub.

About Workiva

Workiva Inc. (NYSE: WK) powers trust, transparency, and accountability. Finance, accounting, sustainability, risk, and audit teams from more than 6,700 organizations, including over 85% of Fortune 1,000 companies, rely on Workiva for their mission-critical work. Workiva transforms how customers connect data, unify processes, and empower teams in a secure, audit-ready platform. Learn more at workiva.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915584662/en/

Permalink

https://aetoswire.com/en/news/1509202657344

Contacts

Media Contact:

Lauren Covello

Workiva Inc.

press@workiva.com